世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

全身性エリテマトーデス(SLE)治療薬市場:薬剤クラス別(抗マラリア薬、非ステロイド性抗炎症薬(NSAIDS)、細胞障害性・免疫抑制薬、生物学的製剤、その他)、投与形態別(静脈内、皮下、経口)、地域別 2024-2032


Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and Region 2024-2032

全身性エリテマトーデス(SLE)治療薬の世界市場規模は2023年に27億米ドルに達した。今後、IMARC Groupは、市場が2032年までに45億米ドルに達し、2024年から2032年の間に5.83%の成長率(CAGR)を示すと予測してい... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IMARC Services Private Limited.
アイマークサービス
2024年1月30日 US$3,899
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
142 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

全身性エリテマトーデス(SLE)治療薬の世界市場規模は2023年に27億米ドルに達した。今後、IMARC Groupは、市場が2032年までに45億米ドルに達し、2024年から2032年の間に5.83%の成長率(CAGR)を示すと予測している。SLEに罹患する患者数の増加、国民の意識向上キャンペーンの高まり、ジェネリック医薬品の容易な入手が市場を牽引する主な要因のいくつかである。

全身性エリテマトーデス(SLE)は、多彩な臨床症状、多系統炎症(MIS)、再発寛解型経過(RRMS)を特徴とする自己免疫疾患である。SLEは、皮膚、関節、腎臓、脳など身体の多くの部位に発症する。一般に、さまざまな遺伝的、環境的、ホルモン的要因によって引き起こされる。症状としては、疲労、関節痛や腫れ、頭痛、発疹、脱毛、貧血、血液凝固、発熱などがあります。SLEは症状評価、身体診察、胸部X線検査、尿検査、血液検査などを行い、医療従事者によって診断されます。関節の痛みやこわばりには抗炎症薬を、発疹にはステロイドクリームを、免疫反応を抑えるには副腎皮質ステロイドを、皮膚のトラブルには抗マラリア薬を使用して症状を緩和します。さらに重症の場合は、疾患修飾薬や標的免疫系薬剤を使用する。このほか、免疫系の活動を抑制する様々な免疫抑制剤を用いて治療する。

全身性エリテマトーデス(SLE)治療薬の市場動向:
自己免疫疾患の有病率の増加やSLE患者の増加は、世界中でSLE治療薬の需要を牽引している主な要因の一つである。さらに、研究機関や診断機関の数は増加傾向にあり、SLEとその可能な治療法について一般の人々を啓蒙するキャンペーンを実施している。さらに、各国の政府や非政府組織(NGO)は、新規治療薬の開発やSLE治療に関連する創薬標的を特定するための様々なプログラムに投資しています。これに加え、医療インフラや診断技術を改善するための資金が世界的に増加していることが、市場の成長を促している。これとは別に、SLEに伴う痛み、炎症、こわばりを和らげるための様々なジェネリック医薬品が、オフラインやオンラインの小売チャネルを通じて簡単に入手できることも、市場の成長を後押ししている。一般に、アスピリン、イブプロフェン(Motrin)、ナプロキセン、セレコキシブ(Celebrex)、ジクロフェナク(Voltaren)、ジフルニサール(Dolobid)、ピロキシカム(Feldene)などの市販薬(OTC)や処方箋ベースの非ステロイド性抗炎症薬(NSAIDs)が使用されている。さらに、ヒドロキシクロロキン製剤の使用増加が市場成長に寄与している。このほか、SLEの早期診断・早期治療の利点に対する個人や医療従事者の意識の高まりが、SLE治療薬の売上全体に影響を与えている。

主な市場セグメンテーション
IMARC Groupは、世界の全身性エリテマトーデス(SLE)治療薬市場の各セグメントにおける主要動向の分析と、2024年から2032年までの世界、地域、国レベルでの予測を掲載しています。当レポートでは、薬剤クラスとデリバリー様式に基づいて市場を分類しています。

薬剤クラスの洞察

抗マラリア薬
クロロキン
ヒドロキシクロロキン
非ステロイド性抗炎症薬(NSAIDS)
細胞毒性薬および免疫抑制薬
シクロホスファミド
メトトレキサート
ミコフェノール酸モフェチル
タクロリムス
シクロスポリン
生物製剤
その他

本レポートでは、全身性エリテマトーデス(SLE)治療薬市場を薬剤クラス別に詳細に分類・分析しています。これには抗マラリア薬(クロロキン、ヒドロキシコロキン)、非ステロイド性抗炎症薬(NSAIDS)、細胞毒性・免疫抑制薬(シクロファミド、メトトレキサート、ミコフェノール酸モフェチル、タクロリムス、シクロスポリン)、生物学的製剤、その他が含まれる。報告書によると、細胞毒性・免疫抑制剤が最大のセグメントを占めている。

送達様式の洞察:

静脈注射
皮下投与
経口

全身性エリテマトーデス(SLE)治療薬市場について、投与形態に基づく詳細な分類と分析も行っている。これには静脈内投与、皮下投与、経口投与が含まれる。報告書によると、経口剤が最大の市場シェアを占めている。

地域別インサイト

北米
米国
カナダ
アジア太平洋
中国
日本
インド
韓国
オーストラリア
インドネシア
その他
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
ロシア
その他
ラテンアメリカ
ブラジル
メキシコ
その他
中東・アフリカ

また、北米(米国、カナダ)、アジア太平洋(中国、日本、インド、韓国、オーストラリア、インドネシア、その他)、欧州(ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他)、中南米(ブラジル、メキシコ、その他)、中東・アフリカを含む主要地域市場についても包括的に分析している。報告書によると、北米は全身性エリテマトーデス(SLE)治療薬の最大市場である。北米の全身性エリテマトーデス(SLE)治療薬市場を牽引している要因としては、医療へのアクセスが容易であること、SLEの早期診断・早期治療の利点に対する認識が高まっていること、様々なジェネリック医薬品が容易に入手可能であることなどが挙げられる。

競争環境:
本レポートでは、世界の全身性エリテマトーデス(SLE)治療薬市場における競争環境についても包括的に分析しています。主要企業の詳細プロフィールも掲載している。対象企業には、AstraZeneca Plc、Aurinia Pharmaceuticals Inc.、GSK plc、ImmuPharma Plcなどが含まれる。

本レポートで扱う主な質問

1.全身性エリテマトーデス(SLE)治療薬の世界市場規模は?
2.2024年から2032年にかけての全身性エリテマトーデス(SLE)治療薬の世界市場予測成長率は?
3.全身性エリテマトーデス(SLE)治療薬の世界市場を牽引する主要因は何か?
4.COVID-19が全身性エリテマトーデス(SLE)治療薬の世界市場に与えた影響は?
5.薬剤クラスに基づく全身性エリテマトーデス(SLE)治療薬の世界市場の内訳は?
6.全身性エリテマトーデス(SLE)治療薬の世界市場における投与形態別の内訳は?
7.全身性エリテマトーデス(SLE)治療薬の世界市場における主要地域は?
8.全身性エリテマトーデス(SLE)治療薬の世界市場における主要プレイヤー/企業は?

ページTOPに戻る


目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Systemic Lupus Erythematosus (SLE) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Antimalarials Drugs
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Chloroquine
6.1.2.2 Hydroxychloroquine
6.1.3 Market Forecast
6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cytotoxic and Immunosuppressive Drugs
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Cyclophosphamide
6.3.2.2 Methotrexate
6.3.2.3 Mycophenolate Mofetil
6.3.2.4 Tacrolimus
6.3.2.5 Cyclosporine
6.3.3 Market Forecast
6.4 Biologics
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Mode of Delivery
7.1 Intravenous
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Subcutaneous
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Oral
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
9.1 Overview
9.2 Drivers
9.3 Restraints
9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AstraZeneca Plc
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Aurinia Pharmaceuticals Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.3 GSK plc
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 ImmuPharma Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis


List of Figures

Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2023
Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2023
Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2023
Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2023
Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million US$), 2024-2032
Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players

 

ページTOPに戻る


 

Summary

The global systemic lupus erythematosus (SLE) drugs market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.83% during 2024-2032.The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.

Systemic Lupus Erythematosus (SLE) Drugs Market Trends:
The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on drug class and mode of delivery.

Drug Class Insights:

Antimalarials Drugs
Chloroquine
Hydroxychloroquine
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Cytotoxic and Immunosuppressive Drugs
Cyclophosphamide
Methotrexate
Mycophenolate Mofetil
Tacrolimus
Cyclosporine
Biologics
Others

The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.

Mode of Delivery Insights:

Intravenous
Subcutaneous
Oral

A detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the mode of delivery has also been provided in the report. This includes intravenous, subcutaneous, and oral. According to the report, oral accounted for the largest market share.

Regional Insights:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc.

Key Questions Answered in This Report

1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?
2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2024-2032?
3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?



ページTOPに戻る


Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Systemic Lupus Erythematosus (SLE) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Antimalarials Drugs
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Chloroquine
6.1.2.2 Hydroxychloroquine
6.1.3 Market Forecast
6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cytotoxic and Immunosuppressive Drugs
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Cyclophosphamide
6.3.2.2 Methotrexate
6.3.2.3 Mycophenolate Mofetil
6.3.2.4 Tacrolimus
6.3.2.5 Cyclosporine
6.3.3 Market Forecast
6.4 Biologics
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Mode of Delivery
7.1 Intravenous
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Subcutaneous
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Oral
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
9.1 Overview
9.2 Drivers
9.3 Restraints
9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AstraZeneca Plc
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Aurinia Pharmaceuticals Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.3 GSK plc
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 ImmuPharma Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis


List of Figures

Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2023
Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2023
Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2023
Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2023
Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million US$), 2024-2032
Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

IMARC Services Private Limited. 社の最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/08 10:26

154.13 円

166.76 円

202.76 円

ページTOPに戻る